

Document and Entity Information	9 Months Ended	
	Jun. 30, 2014	Aug. 13, 2014
<b>Document and Entity Information [Abstract]</b>		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	0001112372	
Amendment Flag	false	
Current Fiscal Year End Date	--09-30	
Document Type	10-Q	
Document Period End Date	Jun. 30, 2014	
Document Fiscal Year Focus	2014	
Document Fiscal Period Focus	Q3	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		83,804,627

Consolidated Balance Sheets (USD (\$))	Jun. 30, 2014	Sep. 30, 2013
<b>Current Assets</b>		
Cash and cash equivalents	\$ 1,765	\$ 1,020
Accounts receivable	13,717	66,209
Inventories	290,142	293,693
Prepaid expenses	5,672	33,730
Total Current Assets	311,296	394,652
<b>Long Term Investment</b>		
Investment in MIT China Joint Venture		
<b>Property and Equipment</b>		
Tooling and machinery	688,011	720,594
Furniture and office equipment	139,548	144,312
Leasehold improvements	28,710	28,487
Total property and equipment	856,269	893,393
Less accumulated depreciation	(639,001)	(707,496)
Total property and equipment, net	217,268	185,897
<b>Other Assets</b>		
Patents (net of accumulated amortization of \$48,523 and \$25,303)	63,073	33,592
Total assets	591,637	614,141
<b>Current Liabilities</b>		
Bank line	74,976	63,200
Deferred income	7,991	
Accounts payable and accrued expenses	129,475	121,944
Amounts due to related parties	20,000	
Current portion of long term debts	51,442	51,442
Total current liabilities	283,884	236,586
Long-Term Debts	51,586	91,606
Total Liabilities	335,470	328,192
<b>Stockholders' Equity (Deficit)</b>		
Preferred stock, \$.0001 par value; 3,000,000 shares authorized; No issued and outstanding shares		
Common stock, \$.0001 par value; 100,000,000 shares authorized; 83,804,627 shares and 83,804,627 issued and outstanding, respectively	7,979	7,979
Additional paid-in capital	12,867,476	12,867,476
Deficit	(12,305,627)	(12,189,399)
Other comprehensive income (loss)	(313,661)	(400,107)
Total Stockholders' Equity (Deficit)	256,167	285,949
Total Liabilities and Stockholders' Equity (Deficit)	\$ 591,637	\$ 614,141

Consolidated Balance Sheets (Parenthetical) (USD \$)	Jun. 30, 2014	Sep. 30, 2013
<b>Balance Sheet [Abstract]</b>		
Accumulated amortization (Patents)	\$ 48,523	\$ 25,303
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	83,804,627	83,804,627
Common stock, shares outstanding	83,804,627	83,804,627

Consolidated Statements of Operations (Unaudited) (USD \$)	3 Months Ended		9 Months Ended	
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
<b>Statements of Operations [Abstract]</b>				

Sales	\$ 152,436	\$ 238,158	\$ 299,280	\$ 528,310
Cost of sales	(35,913)	(97,307)	(86,563)	(166,897)
Gross profit (loss)	116,523	140,851	212,717	361,413
Selling, general, and administrative expenses	(147,963)	(336,492)	(320,240)	(540,371)
Total operating expenses	(147,963)	(336,492)	(320,240)	(540,371)
Loss from operations	(31,440)	(195,641)	(107,523)	(178,958)
Other Income (Expense) Equity earnings (loss) on MIT China Joint Venture		(90,445)		(144,065)
Interest income/loss	297	539	1,246	760
Interest expense	(4,282)	(5,997)	(9,951)	(11,521)
Other income (expense), net	(3,985)	(95,903)	(8,705)	(154,826)
Net Loss	\$ (35,425)	\$ (291,544)	\$ (116,228)	\$ (333,784)
Basic (loss) per share	\$ (0.0004)	\$ (0.003)	\$ (0.001)	\$ (0.004)
Basic weighted average shares outstanding	83,804,627	83,804,627	83,804,627	83,804,627

Consolidated Statements of Cash Flows (USD \$)	9 Months Ended	
	Jun. 30, 2014	Jun. 30, 2013
<b>Cash flows from operating activities:</b>		
Net loss	\$ (116,228)	\$ (333,784)
<b>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</b>		
Equity loss from MIT China Joint Venture		144,065
Depreciation and amortization expense	63,519	94,880
Related party payables settle by common stock	20,000	
Capitalization of related party debts		
<b>Changes in:</b>		
Accounts receivable	52,492	19,080
Inventories	3,551	9,493
Prepaid expenses	28,057	11,377
Accounts payable and accrued liabilities	7,530	5,900
Deferred income	7,991	(109,479)
Net cash provided (used) by operating activities	66,912	(158,469)
<b>Cash flows from investing activities:</b>		
Acquisition of patents	(6,369)	(5,251)
Net cash used by investing activities	(6,369)	(5,251)
<b>Cash flows from financing activities:</b>		
Bank line	11,776	(92,147)
Bank loans	(40,020)	(48,226)
Net cash used by financing activities	(28,224)	(132,367)
Effect of exchange rates	(31,554)	8,487
Increase (decrease) in cash	745	(295,606)
Cash, beginning of period	1,020	303,497
Cash, end of period	1,765	7,981
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	9,952	10,762
Cash paid for federal income taxes		

Consolidated Statements of Comprehensive Loss (USD \$)	9 Months Ended	
	Jun. 30, 2014	Jun. 30, 2013
<b>Statements of Comprehensive Loss [Abstract]</b>		
Net loss	\$ (116,228)	\$ (333,784)
<b>Other comprehensive income (loss)</b>		
Foreign currency translation adjustment	86,446	(12,107)
Net comprehensive loss	\$ (29,782)	\$ (345,891)

Consolidated Statement of Stockholders' (Deficit) (USD \$)	Total	Common Stock	Additional Paid-In Capital	Deficit
Beginning Balance at Sep. 30, 2013	\$ 285,949	\$ 7,979	\$ 12,867,386	\$ (12,189,399)
Beginning Balance, Shares at Sep. 30, 2013		83,804,627		
Shares issued for debts				
Shares issued for debts, Shares				
shares issued for services				
shares issued for services, Shares				
Shares issued for additional capital				
Shares issued for additional capital, Shares				
Net loss	(116,228)			(116,228)

Balance at Jun. 30, 2014	\$ 256,167	\$ 7,979	\$ 12,867,386	\$ (12,305,627)
Balance, Shares at Jun. 30, 2014		83,894,627		

Basis of Presentation	9 Months Ended	
	Jun. 30, 2014	
<b>Basis of Presentation [Abstract]</b>		
Basis of Presentation	<b>Note 1 – Basis of Presentation</b>	
	<b>Interim Financial Statements</b>	
	<p>The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. (“MIT” or the “Company”) and its subsidiary (collectively referred to as the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2013.</p> <p>In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2014 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2014. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p>	

Inventories	9 Months Ended									
	Jun. 30, 2014									
<b>Inventories [Abstract]</b>										
Inventories	<b>Note 2 – Inventories</b>									
	<p>Inventories at June 30, 2014 and September 30, 2013 consist of the following:</p>									
	<table border="0"> <tr> <td>Raw materials</td> <td></td> </tr> <tr> <td>Work in process</td> <td></td> </tr> <tr> <td>Finished goods</td> <td></td> </tr> <tr> <td>Total</td> <td></td> </tr> </table>		Raw materials		Work in process		Finished goods		Total	
Raw materials										
Work in process										
Finished goods										
Total										

Property and Equipment	9 Months Ended	
	Jun. 30, 2014	
<b>Property and Equipment [Abstract]</b>		
Property and Equipment	<b>Note 3 – Property and Equipment</b>	
	<p>The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the nine months ended June 30, 2014 and 2013 was \$48,523 and \$84,730, respectively</p>	

Intangible Assets	9 Months Ended	
	Jun. 30, 2014	
<b>Intangible Assets [Abstract]</b>		
Intangible Assets	<b>Note 4 – Intangible Assets</b>	
	<p>As of June 30, 2014 the Company has net patents on certain technologies aggregating \$63,073. Amortization expense for the nine months ended June 30, 2014 and 2013, needle-free injector of \$34,831. Following is a detail of patents at June 30, 2014.</p>	
	Patents	\$

Gr  
Intar  
As

Joint Venture Agreement	9 Months Ended	
	Jun. 30, 2014	
<b>Joint Venture Agreement [Abstract]</b>		
Joint venture agreement	<b>Note 5 – Joint venture agreement</b>	
	<p>On May 6, 2009, the Company entered into a certain joint venture agreement (the “Joint Venture Agreement”) with Jiangsu Hualan Biotechnology Ltd. (China) (“Jiangsu Hualan”). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. (“MIT China” or the “Joint Venture”), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company’s needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of \$714,000, and owns 51% of the registered capital.</p> <p>Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party’s investment in the registered capital.</p>	

In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US\$3,000,000). Jiangsu Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.

The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of June 30, 2014 and September 30, 2013, the Company's had no recorded investment remaining in the MIT China.

Bank Line	9 Months Ended Jun. 30, 2014
<b>Bank Line [Abstract]</b>	
Bank Line	<b>Note 6 – Bank Line</b>
	The Company, through a hypothec agreement, has a line of credit up to a maximum of \$100,000. The line is secured by Investissement Quebec (a Quebec government entity), by Karim Menassa (personally) and by account receivables, inventories, equipment and all other assets of the Company. At June 30, 2014 and September 30, 2013, the Company had \$74,980 and \$63,200 outstanding under the agreement.

Related Party Transactions	9 Months Ended Jun. 30, 2014
<b>Related Party Transactions [Abstract]</b>	
Related Party Transactions	<b>Note 7 – Related Party Transactions</b>
	Related party balances consist of the following at June 30, 2014 and September 30, 2013:
	Payable to 9211-0766 Quebec Inc
	The Company has borrowed from shareholders and corporations owned by shareholders. These loans are bearing interest at 8%, and are due during fiscal 2014.

Stockholders' Equity (Deficit)	9 Months Ended Jun. 30, 2014
<b>Stockholders' Equity (Deficit) [Abstract]</b>	
Stockholders' Equity (Deficit)	<b>Note 8 – Stockholders' Equity (Deficit)</b>
	<b>Issuance of Common Stock</b>
	From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.
	For the three and nine months ended June 30, 2014, there were no common stock issuances.
	<b>Preferred Stock</b>
	As of June 30, 2014, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.
	<b>Outstanding Options and Warrants</b>
	As of June 30, 2014 and September 30, 2013, there are no options or warrants outstanding to purchase shares of the Company's common stock.

Operating Leases	9 Months Ended Jun. 30, 2014
<b>Operating Leases [Abstract]</b>	
Operating Leases	<b>Note 9 – Operating Leases</b>
	The Company leases its office and warehouse space under an operating lease that expires on December 31, 2014 that calls for a monthly rent of \$4, 250. Rent expense for the nine months ended June 30, 2014 was approximately 36,000.

Notes Payable	9 Months Ended Jun. 30, 2014
<b>Notes Payable [Abstract]</b>	
Notes Payable	<b>Note 10 – Notes Payable</b>
	Long-term debt consists of the following at June 30, 2014 and September 30, 2013:
	Note payable to a bank, bearing interest at prime plus 3%, secured by equipment, due June 21, 2016.
	Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installment starting twelve (12) month a
	Total long-term debt
	Current portion of long-term debt
	Long-term debt, net of current portion

Future scheduled principal payments under note agreements are as follows:

Year ended
June 30, 2015
June 30, 2016

Contingencies	9 Months Ended
Contingencies [Abstract]	Jun. 30, 2014
Contingencies	<b>Note 11 – Contingencies</b>
	<b>Legal Proceedings</b>
	We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Inventories (Tables)	9 Months Ended
Inventories [Abstract]	Jun. 30, 2014
Components of inventory	
	Raw materials
	Work in process
	Finished goods
	Total

Intangible Assets (Tables)	9 Months Ended
Intangible Assets [Abstract]	Jun. 30, 2014
Summary of patents	
	Gr Intar As
	Patents \$

Related Party Transactions (Tables)	9 Months Ended
Related Party Transactions [Abstract]	Jun. 30, 2014
Summary of related party transactions	
	Payable to 9211-0766 Quebec Inc

Notes Payable (Tables)	9 Months Ended
Notes Payable [Abstract]	Jun. 30, 2014
Schedule of long-term debt	
	Note payable to a bank, bearing interest at prime plus 3%, secured by equipment, due June 21, 2016.
	Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installment starting twelve (12) month a
	Total long-term debt
	Current portion of long-term debt
	Long-term debt, net of current portion
Future scheduled principal payments of long-term debt	<b>Year ended</b>
	June 30, 2015
	June 30, 2016

Inventories (Details) (USD \$)	Jun. 30, 2014	Sep. 30, 2013
<b>Components of inventory</b>		
Raw materials	\$ 213,455	\$ 216,053
Work in process	66,294	66,858
Finished goods	10,393	10,782
<b>Total</b>	<b>\$ 290,142</b>	<b>\$ 293,693</b>

Property and Equipment (Details) (USD \$)	9 Months Ended	
	Jun. 30, 2014	Jun. 30, 2013
<b>Property and Equipment (Textual)</b>		
Depreciation expense	\$ 48,523	\$ 84,730
<b>Minimum [Member]</b>		
<b>Property and Equipment (Textual)</b>		
Estimated useful lives of property and equipment	5 years	
<b>Maximum [Member]</b>		
<b>Property and Equipment (Textual)</b>		
Estimated useful lives of property and equipment	7 years	

Intangible Assets (Details) (USD \$)	9 Months Ended				
	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2014 Patents [Member]	Jun. 30, 2014 Minimum [Member] Patents [Member]	Jun. 30, 2014 Maximum [Member] Patents [Member]
<b>Detail of patents</b>					
Gross Intangible Assets			\$ 99,976		
Accumulated amortization (Patents)	48,523	25,303	36,903		
<b>Net Intangible Assets</b>	<b>\$ 63,073</b>	<b>\$ 33,592</b>	<b>\$ 63,073</b>		
Weighted Average Life (Years)				7 years 6 months	15 years

Intangible Assets (Details Textual) (USD \$)	9 Months Ended		
	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2013
<b>Patents (Textual)</b>			
Aggregate net patents	\$ 63,073		\$ 33,592
Amortization expenses	14,996	10,149	
Capitalized patent costs on needle-free injector	\$ 34,831		

Joint Venture Agreement (Details)	0 Months Ended	1 Months Ended		3 Months Ended		9 Months Ended		0 Months Ended	0 Months Ended	0 Months Ended	
	May 06, 2009 USD (\$) Members	Mar. 31, 2012 USD (\$)	Mar. 31, 2012 CNY	Jun. 30, 2014 USD (\$)	Jun. 30, 2013 USD (\$)	Jun. 30, 2014 USD (\$)	Jun. 30, 2013 USD (\$)				Sep. 30, 2013 USD (\$)
<b>Joint Venture Agreement (Textual)</b>											
Ownership percentage	49.00%	44.59%	44.59%						51.00%	46.41%	9.00%
Cash invested in joint venture		\$ 3,000,000	18,000,000						\$ 714,000		
Total investment to be made by joint venture	2,000,000										
Number of members appointed under joint venture agreement	1								2		
Registered capital	1,400,000										
Investment in joint venture	426,678										
Value of license rights	280,000										
Sale of joint venture percentage for an investment by parent company		9.00%	9.00%								
Equity loss from MIT China Joint Venture						\$ (90,445)			\$ (144,065)		

Bank Line (Details) (USD \$)	Jun. 30, 2014	Sep. 30, 2013
<b>Bank Line (Textual)</b>		
Maximum equipment line of credit	\$ 100,000	
Amount outstanding	\$ 74,980	\$ 63,200

Related Party Transactions (Details) (USD \$)	Jun. 30, 2014	Sep. 30, 2013
<b>Related Party Transactions [Abstract]</b>		
Payable to 9211-0766 Quebec Inc	\$ 20,000	
Amounts due to related parties, Total	\$ 20,000	

Related Party Transactions (Details Textual)	9 Months Ended	
	Jun. 30, 2014	
<b>Related Party Transactions [Abstract]</b>		
Related party transactions loans interest rate		8.00%

Operating Leases (Details) (USD \$)	9 Months Ended	
	Jun. 30, 2014	
<b>Operating Leases (Textual)</b>		
Expiry date of operating lease	Dec. 31, 2014	
Monthly rent for office and warehouse space		\$ 4,250
Rent expense		\$ 36,000

Notes Payable (Details) (USD \$)	Jun. 30, 2014	Sep. 30, 2013
<b>Schedule of long-term debt</b>		
Note payable to a bank, bearing interest at prime plus 3%, secured by equipment, due June 21, 2016.	\$ 65,274	\$ 89,194
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	37,754	53,854
Total long-term debt	103,028	143,048
Current portion of long-term debt	(51,442)	(51,442)
Long-term debt, net of current portion	\$ 51,586	\$ 91,606

Notes Payable (Details 1) (USD \$)	Jun. 30, 2014	Sep. 30, 2013
<b>Future scheduled principal payments of long-term debt</b>		
June 30, 2015	\$ 51,442	
June 30, 2016	144	
Total long-term debt	\$ 51,586	\$ 91,606

Notes Payable (Details Textual)	9 Months Ended	
	Jun. 30, 2014	
<b>Notes Payable (Textual)</b>		
Number of consecutive installments for repayment of long-term debt		16
<b>Notes payable to bank [Member]</b>		
<b>Notes Payable (Textual)</b>		
Interest rate in addition to prime rate		3.00%
Debt maturity date	Jun. 21, 2016	
<b>Canada economic development [Member]</b>		
<b>Notes Payable (Textual)</b>		
Due date of first installment	Twelve (12) month after the project completion date.	

#### The rendering log information

Info : Element us-gaap\_EarningsPerShareBasic had a mix of decimals attribute values: 3 4.  
 Info : Element us-gaap\_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 2 4.  
 Info : Process Flow -Through: 002 - Statement - Consolidated Balance Sheets  
 Info : Process Flow -Through: Removing column 'Jun. 30, 2013USD (\$)'  
 Info : Process Flow -Through: Removing column 'Mar. 31, 2013USD (\$)'  
 Info : Process Flow -Through: Removing column 'Sep. 30, 2012USD (\$)'  
 Info : Process Flow -Through: Removing column 'Mar. 31, 2012USD (\$)'  
 Info : Process Flow -Through: Removing column 'Mar. 31, 2012CNY'  
 Info : Process Flow -Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical)  
 Info : Process Flow -Through: 004 - Statement - Consolidated Statements of Operations (Unaudited)  
 Info : Process Flow -Through: 005 - Statement - Consolidated Statements of Cash Flow s  
 Info : Process Flow -Through: 006 - Statement - Consolidated Statements of Comprehensive Loss